secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001104659-25-061875
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma provides update on lead asset IBA101; IND filing H2 2025
-------------------------------------------------------------------------

- IBA101 is a next-generation CD47 blockade designed to avoid anemia and thrombocytopenia seen with first-generation drugs.
- Preclinical data show IBA101 plus PD-1/PD-L1 inhibitors gave 2-3x higher complete response rates vs monotherapy.
- IND preparation begins H2 2025 with simultaneous submissions to U.S. FDA and Korea MFDS planned.
- Phase 1 first-in-human study in advanced solid tumors (starting with NSCLC) expected to launch in late 2026.
- Company completed SPAC merger with IRIS Acquisition Corp. and began trading on Nasdaq in May 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925061875/0001104659-25-061875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925061875/tm2518647d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-061875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer